35 trends tracked about this subject — the full history, oldest to newest below.
Recent studies indicate that popular weight-loss medications manufactured by Novo Nordisk and Eli Lilly remain effective at smaller doses.
A large genetic study connects GLP-1 receptor activation to improved mental well-being.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
A new study suggests a genetic link between the use of GLP-1 weight-loss medications and increased hair loss risks for certain men.
Recent studies indicate that GLP-1 weight loss medications may worsen or accelerate hair loss in men.
A growing cultural and medical debate is emerging over the use of GLP-1 medications, focusing on the tension between clinical benefits and social stigma.
Experts call for safer weight loss methods as public and medical attention intensifies around the use and effectiveness of GLP-1 medications.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New scientific discoveries regarding brain circuits may redefine the understood mechanism of GLP-1 weight loss drugs like Ozempic and Wegovy.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Regulators receive hundreds of reports linking popular weight-loss drugs to deaths.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
Australian regulators and medical reports link GLP-1 weight-loss drugs like Ozempic to a rare and severe risk of permanent vision loss.
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.
Recent medical reviews suggest users of GLP-1 weight-loss medications may face significant weight regain after stopping treatment.
A 54-year-old woman's emergency room hospitalization after a GLP-1 overdose highlights rising public safety concerns.
Recent data indicates that 11% of the American population is now utilizing GLP-1 weight loss medications such as Wegovy.
Wegovy weight‑loss pill hits UK shelves today, sparking a predicted rush of tens of thousands of users.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
Parents are increasingly administering weight-loss medications like Wegovy to elementary school children as young as six to combat obesity.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
16 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New research indicates that GLP-1 obesity medications may provide unexpected benefits for male fertility by increasing testosterone and sperm quality.
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
GLP-1 weight-loss drugs are exposing a hidden health crisis: nutrient deficiencies linked to rapid weight loss
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes